Ads Top

Covaxin Phase 1 trial result: Bharat Biotech’s COVID-19 vaccine well tolerated with no serious adverse events

The interim findings of phase 1 clinical trial of COVID-19 vaccine Covaxin, indigenously developed by Bharat Biotech in collaboration with the ICMR, showed that it was was well tolerated in all dose groups with no serious or adverse events.

from Lifestyle News:Entertainment News,Bollywood Latest News,Box Office Collection Report,Movie Reviews
Read The Rest:financialexpress...

No comments:

Powered by Blogger.